Nebenwirkungen · Poherdy
Poherdy 420 mg concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 12–13
HOS-153653 · Präparat HOS-101026
12 Diarrhoea In the pivotal trial CLEOPATRA in metastatic breast cancer, diarrhoea occurred in 68.4% of Pertuzumab-treated patients and 48.7% of placebo-treated patients (see section 4.4). Most events were mild to moderate in severity and occurred in the first few cycles of treatment. The incidence of NCI- CTCAE Grade 3-4 diarrhoea was 9.3% in Pertuzumab-treated patients vs 5.1% in placebo-treated patients. The median duration of the longest episode was 18 days in Pertuzumab-treated patients and 8 days in placebo-treated patients. Diarrhoeal events responded well to proactive management with anti- diarrhoeal agents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T12:22:00Z · SHA-256 e51bba73aa849edde25c8bb5504db0140aa175ccec2e74e1ff7ef3ea305b337a · Passage b66d6893d2e737e9c04ca51a72cec1a91e1a71cdecf5efe96326d5fa682b60fb · Zeichen 15202–15826 im Abschnitt